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Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage
repair defects are common in different cancer types; these alterations can also induce tumour-specific vulnerabilities that can be
exploited therapeutically. In 2009, a first-in-man clinical trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib
clinically validated the synthetic lethal interaction between inhibition of PARP1, a key sensor of DNA damage, and BRCA1/
BRCA2 deficiency. In this review, we summarize a decade of PARP inhibitor clinical development, a work that has resulted in the
registration of several PARP inhibitors in breast (olaparib and talazoparib) and ovarian cancer (olaparib, niraparib and rucaparib,
either alone or following platinum chemotherapy as maintenance therapy). Over the past 10 years, our knowledge on the
mechanism of action of PARP inhibitor as well as how tumours become resistant has been extended, and we summarise this
work here. We also discuss opportunities for expanding the precision medicine approach with PARP inhibitors, identifying a
wider population who could benefit from this drug class. This includes developing and validating better predictive biomarkers
for patient stratification, mainly based on homologous recombination defects beyond BRCA1/BRCA2 mutations, identifying DNA
repair deficient tumours in other cancer types such as prostate or pancreatic cancer, or by designing combination therapies
with PARP inhibitors.
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A deeper understanding of the molecular make up of tumours
has brought opportunities to develop more precise treatments,
targeting tumour vulnerabilities. Inhibitors of poly(ADP-ribose)
polymerase (PARP) are examples of the path towards precision
medicine. In this manuscript, we review the clinical development
of PARP inhibitors (PARPi) across tumour types, leading to
approvals in breast and ovarian cancer, and analyse opportunities
ahead to optimize the use of this drug class.
Fast-track for translational research: the
launch of PARPi clinical development
In 2005, two seminal studies demonstrated that tumour cells
lacking BRCA1 or BRCA2, key tumour suppressor proteins
involved in double-strand DNA break (DSB) repair by
homologous recombination (HR), are selectively sensitive to
small molecule inhibitors of the PARP family of DNA repair
enzymes [1, 2]. The model proposed was based on the concept of
synthetic lethality: loss of either of two genes is not lethal per se,
but concomitant inactivation leads to cell death. PARP1, the
major target of PARPi, is primarily involved in the repair of
single-strand DNA breaks (SSBs); PARP1 inhibition alone is not
lethal as the DNA lesions caused by these drugs can be repaired
by other DNA repair pathways, specifically HR. In contrast, in
the absence of BRCA1/2 and therefore defective HR, the DNA
lesions caused by PARPi are not repaired and cause cytotoxicity.
In these studies, decreasing PARP1 levels by RNA interference
also resulted in a significant reduction of cell survival selectively
in BRCA1- and BRCA2-deficient cells [1]. Cancer cell lines lack-
ing BRCA1/2 were also sensitive to inhibitors of PARP1, whereas
cells with only heterozygous loss of BRCA1/2 genes or those
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without BRCA1/2 defects were not. In a back-to-back publica-
tion, depletion of BRCA2 using short-interfering RNA (siRNA)
sensitized cancer cell lines to PARP inhibition [2]. Later studies
demonstrated how loss of other tumour suppressor DNA repair
proteins, many of which are involved in HR, also caused sensi-
tization to PARPi [3–5].
PARPi were originally developed for cancer treatment as radio-
and chemo-sensitizing drugs, but the aforementioned preclinical
observations supported the development of PARPi as single
agents for the treatment of BRCA1/2-defective cancers. In 2005,
most of the data on BRCA1/2 related to the role of these genes as
risk susceptibility factors for familial breast and ovarian cancers.
Given this, germline BRCA1/2 (gBRCA1/2) mutation carriers
with cancer were the initial target population to test the PARPi-
BRCA synthetic lethal hypothesis in the clinic. A first-in-human
clinical trial of KU-0059436 (KuDOS Pharmaceuticals/
AstraZeneca, later named AZD-2281/olaparib) was conducted to
establish a recommended dose and to generate preliminary data
in a biomarker-defined population [6, 7]. In this proof-of-
concept trial, pharmacokinetics and pharmacodynamics [in per-
ipheral mononuclear blood cells (PBMC), hair follicles, and tu-
mour samples) studies were used to optimize the dose-escalation
and expansion phases. Expansion cohorts only included patients
with gBRCA1/2mutations. Doses of 60mg or more twice daily of
olaparib resulted in>90% PARP1 inhibition in PBMCs, suggest-
ing biological activity at low doses. Dose-limiting toxicities of fa-
tigue, somnolence and thrombocytopenia led to establishing
400mg of olaparib capsules twice daily as the maximum tolerated
dose. A modified tablet formulation with enhanced bioavailabil-
ity was later developed; the current olaparib approved dose is
300mg tablet twice a day [8]. Importantly, gBRCA1/2 mutation
carriers did not experience enhanced toxicities, supporting the
hypothesis of a cancer-specific vulnerability. Overall, 21 gBRCA1/
2 mutation carriers were enrolled and evaluated for response,
with radiological responses in eight patients with ovarian cancer
and one with breast cancer, and a prostate cancer patient with a
sustained PSA response.
This rapid translation of preclinical studies into promising
clinical data triggered the development of several PARPi in differ-
ent tumour types.
Mechanisms of action of PARPi: beyond
synthetic lethality
PARP1 is a DNA damage sensor and signal transducer that binds
to DNA breaks and then synthesises poly(ADP-ribose) (PAR)
chains on target proteins (PARylation) in the vicinity of the DNA
break and itself (autoPARylation). These PAR chains lead to the
recruitment of additional DNA repair effectors that complete the
DNA repair process. In its non-DNA bound state, PARP1 has
minimal catalytic activity due to an auto-inhibitory helical do-
main (HD) interaction with its catalytic domain [9]. When
PARP1 binds DNA, via zinc finger domains, a conformational
change in the PARP1 protein relieves the autoinhibitory inter-
action between the HD and the catalytic domain, allowing nico-
tinamide adenine dinucleotide (b-NADþ), the PARP1 co-factor,
to bind the active site of the enzyme. PARP1 then uses the hy-
drolysis of b-NADþ to catalyse the transfer of ADP-ribose
moieties on to target proteins. This PARylation of proteins in the
vicinity of the DNA breaks then likely mediates DNA repair by
modifying chromatin structure (e.g. via histone-PARylation) and
by localizing DNA repair effectors (e.g. XRCC1). PARP1
autoPARylation eventually leads to its own release from the site
of DNA damage [9, 10].
Pharmacological PARPi structurally mimic nicotinamide, and
have two general effects: (i) catalytic inhibition of PARP1 (i.e.
preventing PARylation) and (ii) locking or ‘trapping’ PARP1 on
damaged DNA. Although the precise mechanisms that explain
PARP1 trapping are still unclear, two have been proposed: (i)
PARPi either prevents the release of PARP1 from DNA by inhib-
iting autoPARylation [11] or (ii) PARPi binding to the catalytic
site causes allosteric changes in the PARP1 structure enhancing
DNA avidity [3, 10, 12]. Either way, trapped PARP1 stalls the
progress of replication forks (Figure 1). In normal, non-tumour
cells, these stalled replication forks would be repaired by HR. In
tumour cells that lack one of the key HR proteins, such as
BRCA1, BRCA2, PALB2, or RAD51, cells use alternative DNA re-
pair mechanisms in an attempt to repair DNA lesions caused by
PARP inhibition, primarily through non-homologous or micro-
homology mediated end-joining (NHEJ or Alt-NHEJ). Rather
than restoring the damaged DNA sequence back to its native
form, the use of error-prone DNA repair pathways leads to a frag-
mentation of the genome that ultimately kills the cell.
Several PARPi in clinical development have different potencies
as PARP1 catalytic inhibitors and as PARP-‘trappers’. It has been
suggested that PARPi that are weak PARP1 trappers (e.g. veli-
parib), fail to elicit the same scale of synthetic lethality in pre-
clinical models, compared with effective trappers (e.g. rucaparib,
olaparib, talazoparib, niraparib) [13]. At present, no clinical trial
has compared head-to-head different PARPi. Of note, iniparib
(BiPar Sciences/Sanofi) was a compound developed as PARPi,
but based on the alternative premise of altering PARP1 zinc-
fingers (disturbing its activation by DNA breaks). After an unsuc-
cessful phase III study in triple-negative breast cancer, preclinical
work demonstrated that iniparib was not a bona fide PARPi [14].
In addition, PARP1 also binds directly to DNA to act as tran-
scription factor and regulate chromatin structure remodelling.
Recently, the role of PARP1 as transcriptional regulator for nu-
clear factors has raised some interest, due to the role of estrogen/
progesterone and androgen receptors in breast and prostate can-
cer, respectively [15].
PARPi development across tumour types
Development of PARPi in ovarian cancer
Following the phase I trial, a phase II study assigned 33 patients
with high-grade epithelial ovarian cancer (HGOC) and gBRCA
mutations in a non-randomized manner to receiving olaparib at
doses of either 100 (biologically active dose) or 400mg (max-
imum tolerated dose) twice daily [16]. The primary end point
was objective response rate (ORR), this being 33% at 400mg
b.i.d. and 13% at 100mg b.i.d. PFS was also longer in the 400mg
cohort (median 5.8 versus 1.9months). This dose–response rela-
tionship, was also suggested in another randomized trial (400
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versus 200mg), which also included a third arm of pegylated lip-
osomal doxorubicin (PLD). Median PFS was 6.5months (95%
CI 5.5–10.1), 8.8months (95% CI 5.4–9.2), and 7.1months (95%
CI 3.7–10.7) for the olaparib 200mg, olaparib 400mg, and PLD
cohorts, respectively [17].
A multicentre phase II study enrolled 65 HGOC patients, re-
gardless of gBRCA status. Confirmed RECIST responses with ola-
parib were seen in 41% and 24% of gBRCAmutation carriers and
non-carriers, respectively [18], suggesting there could be a target
population beyond gBRCA mutation carriers. Around 15% of
HGOC are associated with gBRCA1/2 mutations (albeit regional
differences). Some additional 6%–8% of patients can have tu-
mour, not germline, BRCA1/2mutations. Mutations in other HR
genes such as RAD50, RAD51C/D, CDK12, or PALB2 are less
common (<1%–3% each) [19].
All of these studies were conducted in populations previously
exposed to platinum chemotherapy, the standard of care for
ovarian cancer. There is a clear association between the
platinum-sensitivity, defined based on the time gap from last
platinum exposure to disease progression, and response to
PARPi [20]. Platinum salts are DNA damaging agents and cause
DNA cross-links that are in part repaired by HR. Hence, DNA re-
pair deficient tumours are expected to be highly sensitive to plat-
inum. At the same time, if resistant clones have restored DNA
repair capacities, some cross-resistance with PARPi is expected
[21]. Clinical trials in ovarian cancer shifted towards using
PARPi as ‘maintenance’ therapy in patients who responded to
platinum-based chemotherapy. The key initial study, olaparib’s
study 19, was carried out in high-grade serous ovarian cancer
patients with platinum-sensitive relapse. This study met its pri-
mary end point, with improved PFS against placebo (8.4 versus
4.8m, HR 0.35), even more pronounced in patients with germ-
line/somatic BRCA1/2 mutations (11.2 versus 4.3m, HR 0.18)
[22, 23]. This led to the approval of olaparib as maintenance
treatment of BRCA1/2-mutated patients in 2014; in 2018, the ap-
proval was expanded to all platinum-sensitive patients, regardless
of BRCA1/2 status. The confirmatory phase III trial, SOLO-2
using the new tablet formulation in gBRCA1/2 mutation carriers
confirmed these results (median PFS 19.1 versus 5.5m for ola-
parib and placebo, respectively) [24]. In 2018, the phase III
SOLO1 trial demonstrated an unprecedented benefit for olaparib
versus placebo (HR PFS 0.30) in the maintenance setting after
first-line platinum-based chemotherapy in FIGO stage III/IV
high-grade ovarian cancer [25]. Based on these studies, olaparib
is now also approved by the FDA for first-line maintenance of
germline/somatic BRCA1/2-mutated HGOC (including fallopian
tube or primary peritoneal cancer). Beyond the maintenance set-
ting, olaparib is also FDA-approved for the treatment of
gBRCA1/2-mutated ovarian cancer progressing to three or more
prior lines of chemotherapy.
At present, two other PARPi have received approval for the
treatment of ovarian cancer patients: niraparib and rucaparib.
Niraparib (previously MK4827, Merck/Tesaro) was first tested
in a dose-escalation trial that established a recommended dose of
300mg twice daily based on dose-limiting toxicities of fatigue,
pneumonitis and thrombocytopenia [26]. Pharmacodynamic
analyses confirmed PARP inhibition50% at doses80mg/day,
with responses observed 60mg/day. Forty percent of 20
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Figure 1. Proposed mechanisms for PARPi activity in HRR-deﬁcient cells. PARP inhibition impairs repair of single strain breaks (SSBs) by dis-
rupting the base excision repair (BER) pathway and also causing PARP1 trapping by inhibiting auto-PARylation and/or PARP release from
DNA. These result in unresolved DNA double-strand breaks (DSBs) that in homologous recombination repair (HRR)-deﬁcient cells lead to cell
death.
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gBRCA1/2 mutation carriers with ovarian cancer achieved
RECIST responses, with antitumour activity also documented in
non-gBRCA associated platinum-sensitive cases. The develop-
ment of niraparib in ovarian cancer has focussed on the post-
platinum maintenance setting, although preliminary results of a
phase II trial evaluating the drug in late-stage disease have been
reported [27]. The phase III NOVA trial randomized 555 patients
with platinum-sensitive recurrent HGOC to maintenance nira-
parib or placebo treatment after second or later line of platinum-
based chemotherapy [28]. The study included two cohorts:
gBRCA mutation carriers (median PFS 21 versus 5.5months,
P< 0.001) and non-gBRCA carriers (median PFS 9.3 versus
3.9months, P< 0.001). In the latter, tumour samples were tested
for genomic signatures associated with HR function defects
[based on the presence of areas with loss-of-heterozygosity, large-
scale state transitions (LST) and telomeric allele imbalance
(TAI)]. Median PFS for the non-gBRCA carriers but signature-
positive patients favoured niraparib (12.9 versus 3.8months,
P< 0.001). Patients without the HR-related signature still
derived some benefit (median PFS 6.9 versus 3.8, P¼ 0.02).
These data suggest that overall platinum-sensitivity status associ-
ates with PARPi sensitivity, although more benefit is seen in
patients with canonical HR defects. This study led to niraparib
being granted FDA and EMA approval in the maintenance set-
ting, regardless of BRCA1/2 status.
Lastly, rucaparib (Clovis Oncology) was initially developed for
IV administration but later evolved into an orally available drug,
with a recommended dose of 600mg twice daily [29, 30]. The
ARIEL3 phase III trial evaluated rucaparib as maintenance treat-
ment following platinum-based therapy in recurrent high-grade
ovarian cancer, randomizing 564 women to rucaparib versus pla-
cebo (2 : 1) [31]. PFS was the primary end point, assessed in a
step-down analysis for three predefined cohorts, namely, (i)
germline/somatic BRCA1/2 mutation present, (ii) HR defect
(HRD)-associated signature based on LOH, and (iii) the intent to
treat population. The association between rucaparib sensitivity
and an LOH-based signature had previously been identified in a
phase II trial of rucaparib (ARIEL2) [32]. Rucaparib was superior
to placebo in terms of PFS in all three cohorts (BRCA1/2-muta-
tion positive: 16.6 versus 5.4months P< 0.001; HRD signature:
13.6 versus 5.4months, P¼0.0001; and intention-to-treat popu-
lation: 10.8 versus 5.4months P¼0.0001). Many of the BRCA1/
2-WT, HRD-positive patients presented mutations in HR genes
such as CHEK2, RAD51C, RAD51D, and RAD54L. These results
led to rucaparib being FDA- and EMA-approved as maintenance
treatment of HGOC regardless of BRCA1/2 status. In addition,
rucaparib is also registered by the FDA and EMA for BRCA1/2-
mutation associated ovarian cancer who have received at least 2
previous lines of chemotherapy [33].
Development of PARPi in breast cancer
In parallel to the initial ovarian studies, the biologically-active
and the maximum-tolerated doses of olaparib were also tested in
breast cancer in a non-randomized study [34]. This study dem-
onstrated that olaparib (capsules, 400mg b.i.d.) was effective and
safe for patients with a gBRCA1/2 mutation, regardless of hor-
mone receptor status. The ORR was 41% (11/27) and the main
side-effects were fatigue and nausea (41% each), and anaemia
(11% grades 3–4). Despite these initial encouraging results, sev-
eral stumbling blocks delayed the clinical development in breast
cancer [35]. In 2017, results from a randomized phase III trial
(OlympiAD) in HER2-negative, gBRCA1/2mutation-associated,
metastatic breast cancer comparing olaparib with physician’s
treatment choice (capecitabine, eribulin, vinorelbine, or gemcita-
bine) were reported [36]. Olaparib had superior median PFS [7.0
versus 4.2months, HR 0.58 (95% CI 0.43–0.80)], with a delay on
quality of life deterioration (HR 0.44; 95% CI 0.25–0.77), and a
tolerable safety profile with only 4.7% rate of treatment discon-
tinuation due to adverse events. This approach was validated in
another phase III trial with talazoparib administered continuous-
ly compared with the same chemotherapy regimens [37], with a
median PFS of 8.6 versus 5.6months (HR 0.54, 95% CI 0.41–
0.71). Of note, neither of the two trials were powered in their de-
sign to detect overall survival differences. Results from a phase III
trial with niraparib and a similar design (BRAVO,
NCT01905592) are awaited. Both olaparib and talazoparib are
now approved by the FDA.
A phase II study with talazoparib (ABRAZO) [38] also demon-
strated the association between antitumour activity of talazoparib
and longer platinum-free interval.
Several trials are now investigating these therapies in earlier
stages of the disease, including the adjuvant setting
(NCT2032823), based on the hypothesis that fewer tumour
evolution-related resistance mechanisms will be present in earlier
stages of the disease. Talazoparib has also been tested as mono-
therapy in the neoadjuvant setting in patients with gBRCA1/2
mutation in a small phase II trial of 20 patients. Promisingly, the
pCR was 53% and 63% when including residual cancer burden 0
and 1, respectively [39]. Conversely, veliparib, which has lower
trapping potency, has not demonstrated significantly increased
antitumour activity when combined with neoadjuvant platinum-
based chemotherapy [40].
Expanding the indications for PARPi to other
tumour types with HR defects
A basket trial of olaparib in patients with gBRCA1/2 mutations
identified responding patients beyond the ovarian or breast can-
cer population, suggesting that other HR-defective tumours
could be suitable for PARPi treatment [41]. Indeed, the phase I
trials of olaparib, niraparib, and talozaparib have already docu-
mented responses beyond the two now approved indications. A
recent study analysed the prevalence of BRCA1/2 alterations
across tumour types beyond ovarian and breast cancer, in pros-
tate, skin (non-melanoma), endometrial, pancreatic, and biliary
duct cancers the prevalence was 5% [42]. Of those, clinical tri-
als have been reported primarily for prostate and pancreatic
cancer.
DNA repair gene alterations are common in metastatic pros-
tate cancer (mPrC). Several genomic landscape studies have esti-
mated that 8%–12% of all mPrC have BRCA2 mutations and
homozygous deletions, with around half of these cases being
linked to a germline mutation [43, 44]. When including other
HR-related genes (such as PALB2, ATM, BRCA1, FANCA, etc.),
up to 20%–25% of all mPrC harbour gene defects in different
DDR pathways, which represents a significant enrichment when
compared with localized, often indolent, prostate tumours [45].
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The original phase I trial of niraparib included a small prostate
cancer expansion cohort, with promising signs of clinical benefit
[26]. Next, an investigator-initiated phase II study of olaparib in
heavily pretreated mPrC patients documented responses in sev-
eral patients. Using a combined definition of response including
radiological responses, PSA falls, and CTC count conversions,
16/49 patients presented some degree of response. Retrospective
genomic assessment of trial biopsies identified a strong associ-
ation between antitumour activity and alterations in different
DNA repair genes [46]. All eight patients with BRCA1/2 altera-
tions responded to olaparib, many with durable responses for
over 1 year, but mutations in genes such as ATM, PALB2, or
FANCA were also observed in some responding patients. Similar
data have been reported in a preliminary analysis of a phase II
trial of rucaparib [47]. Based on these studies, registration trials
of different PARPi in prostate cancer are now ongoing, although
with different strategies when it comes to defining the putative
predictive biomarker suite. Beyond their use as single agents in
HR-defective tumours, PARP1 is an interesting target in prostate
cancer based on the cross-talk between the androgen receptor
(main oncogenic driver of prostate cancer) and DDR pathways;
results from phase II combination trials of PARPi- and AR-
targeting agents have now been reported [48] and have led to on-
going registration studies.
In the initial phase I study of talozaparib, two patients with
pancreatic cancer and mutations in BRCA2 and PALB2, respect-
ively, achieved radiological partial responses [49]. Platinum-
based chemotherapy represents one of the main systemic treat-
ments for advanced pancreatic cancer. Two recent prospective
trials treated patients with stage III/IV pancreatic adenocarcin-
oma and germline BRCA1, BRCA2, or PALB2 mutations with
veliparib or rucaparib. Response rates were 1/16 for veliparib
[50] and 3/19 for rucaparib [51]. Of note, almost all patients in
these trials had previously progressed on platinum-based chemo-
therapy. In pancreatic cancer, positive results of a phase III trial
of olaparib for maintenance therapy after response to platinum
chemotherapy, following the ovarian cancer model, have recently
been announced. Other strategies currently being investigated in-
clude testing PARPi in combination with chemotherapy or as
radiosensitizing agents.
Developing predictive biomarkers for PARPi
The analytical validation and clinical qualification of biomarkers
able to stratify patients is of critical importance to deliver preci-
sion patient care with this drug class. During early phases of
PARPi development, most efforts centred on detecting gBRCA1/
2 mutations, initially using Sanger sequencing [52]. As interest
has evolved beyond gBRCA1/2 mutations, multiplexed NGS
assays of both germline and somatic DNA have become the pre-
ferred tool for patient identification [53, 54].
Multiplexed NGS panels assess a number of genes of interest
(mostly exonic regions), either through amplification or capture-
based technologies. Clinical implementation of multiplexed
panels is, compared with wider whole-exome (WES) or whole-
genome (WGS) sequencing, easier due to their lower cost and,
critically, lower burden of bioinformatics requirements for data
analysis. Accurate copy number assessment from targeted
sequencing remains challenging, which is critical to demonstrat-
ing biallelic loss of DNA repair genes. This is, in part, due to in-
trinsic limitations in the technology but also relates to the need to
integrate sample tumour purity, ploidy, and intratumour
heterogeneity.
Wider WES or WGS assays add value by covering additional
areas of the genome and by improving copy number and re-
arrangement calling. However, their applicability to clinical
decision-making is still limited. Low-coverage WGS appears as a
promising alternative for accurate and inexpensive copy number
profiling, although it still requires significant bioinformatics
analyses.
Incorporation of multiplexed biomarkers, such as DNA repair
gene defects, has challenged some of the traditional concepts for
biomarker validation in anticancer drug development. New gen-
omic variants in the genes of interest are being identified, some of
these being unique to individual patients. Hence, it is challenging
to pursue clinical qualification of each of these separately in real
time. Orthogonal methods to validate the impact on protein
function of these findings is critical. Moreover, emergence of new
variants also challenges traditional regulatory frameworks,
demanding a continuous reassessment of the data in the post-
approval setting [55]. Two main approaches could help circum-
vent the limitations of multiplexed biomarkers: (i) the identifica-
tion of common genomic or transcriptional signatures in HR
deficient tumours and (ii) assays capable of determining func-
tional states of the HR pathway.
Genomic signatures or scars represent repetitive patterns
of DNA alterations that translate an underlying biological
condition [56]. Tumours deficient for HR prioritize NHEJ
for repair of DSB, resulting in more errors ligating broken
chromosomal ends. These tumours accumulate small
insertions-deletions and loss-of-heterozygosity events [57].
Conversely, tumours with defective mismatch repair accu-
mulate point mutations and tumours harbouring biallelic
CDK12 loss develop a particular genomic profile character-
ized by repetitive tandem duplications, which increase neo-
antigen formation [58–60].
Several assays quantifying LOH events and/or TAI across the
genome have been tested as predictive biomarkers of sensitivity
to PARPi. Two of them have been approved by the FDA as com-
panion diagnostics for PARPi in ovarian cancer: the
‘FoundationFocus CDx BRCA LOH’, evaluates the frequency of
LOH events throughout the genome [57], and the ‘myChoice
HRD’ (Myriad), a composite signature of LOH, TAI, and LST
events. Most of the data on the predictive biomarker value of
such signatures were generated in the randomized trials of nira-
parib and of rucaparib in ovarian cancer. The aim of such signa-
tures is to identify patients likely to respond to PARPi by
harbouring an intrinsic HR defect even when no obvious BRCA1/
2 alterations are detected by NGS. However, these signatures pre-
sent a critical limitation: the mutational/LOH patterns do not re-
vert when a tumour has recovered HR function, so they may not
be accurate to predict PARPi sensitivity in patients who have pre-
viously received and progressed on DNA damaging chemother-
apy, such as platinum.
An alternative approach is to evaluate key DNA repair protein
expression. ATM expression by IHC translates ATM genomic sta-
tus and is associated with survival in patients with colorectal
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Figure 2. Described mechanisms of secondary resistance to PARP inhibitors. The potential mechanisms of PARPi resistance can be classiﬁed
in three main groups: (i) those that result in restoration of homologous recombination repair (HRR), (ii) those leading to mitigation of replica-
tion stress (RS) commonly together with slower cell cycle progression, and (iii) other mechanisms not directly related with an HRR or RS path-
way but that still alter the response to PARPi, such as mutations in PARP1 or drug efﬂuxion pumps.
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cancer treated with platinum [61]. Functional assays may directly
inform on the capacity of the tumour cell to repair damage, trans-
lating upstream DNA/RNA alterations. Assays looking at accu-
mulation of cH2AX (a marker of DNA damage) and RAD51
nuclear foci formation (indicating correct HR repair) are a gold
standard for evaluating HR function in preclinical models. Their
challenge raises from the need to be tested in samples with DNA
damage and proliferating cells, since HR is cell cycle-related [62].
Functional assays evaluating cH2AX-RAD51 recently showed
promising results in breast cancer biopsies, predicting PARPi
sensitivity but also capturing the emergence of secondary resis-
tances [63, 64].
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Figure 3. Rational combinations of PARPi with other targeted agents. Hypothesis-driven combinations with PARP inhibitors are summarized;
(A) combinations of PARPi with other compounds targeting alternatives DDR nodes aim to maximize accumulation DNA damage during G1
and S phases of the cell cycle, together with preventing its repair during G2 by minimizing the time to repair. This would lead to accumula-
tion of DNA damage during mitosis and cell death. (B) Combinations with drugs targeting other biological pathways which have been
shown to be modulated and/or to modulate HRR function, such as the PI3K/AKT pathway, RAS, VEGFR, and AR signalling pathways. (C)
Rationale for developing PARPi-immunotherapy combinations; defects in DDR might increase genomic instability, leading to accumulation
of mutations and, putatively, increased neoantigen production and T-cell activation. An alternative hypothesis supporting PARPi-immuno-
therapy combinations is the accumulation of cytosolic DNA induced by DDR defects, which would activate the innate immune system
through the cGAS-STING pathway, inducing interferon-mediated response. This pro-inﬂammatory cascade would result in activation of NK
cells and macrophages and the inﬁltration, proliferation and antitumour response of CD4þ and CD8þ T cells into the tumour. Paradoxically,
the STING pathway also activates the expression of PD-L1 in tumour cells, therefore limiting the cytotoxic immune response, but potentially
rendering the tumour sensitive to PD-L1 blockade (DC, dendritic cell; M1, macrophage; NK, natural killer cell; Treg, regulatory T cell).
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Acquisition of PARPi resistance
Numerous mechanisms of acquired resistance to PARPi have
been described in pre-clinical and clinical studies [65, 66]; these
can be grouped into three main classes (Figure 2).
First, a number of different mechanisms result in restoration of
HR function. The most common examples are secondary muta-
tions restoring the open reading frame of HR repair genes
(BRCA1/2, PALB2, RAD51C/D) in tumours with frameshift or
nonsense mutations [67–70]. Expression of functional hypomor-
phic variants of BRCA1 has been associated with resistance to
PARPi in patient-derived models [63, 71, 72]. Similarly, while
epigenetic silencing of BRCA1 and RAD51C by hypermethylation
of promoter regions results in PARPi sensitivity, demethylation is
associated with mRNA re-expression and development of resist-
ance [64, 73, 74]. There is also evidence in preclinical models of
the co-existence of other mechanisms of resistance involving, for
example, BRCA1 restoration with the removal of barriers to DNA
end resection via loss of 53BP1 or proteins from the Shieldin
complex, among others [75, 76].
An alternative mechanism for PARPi resistance is the protec-
tion of the replication fork, often combined with slowing cell
cycle progression, as described in several preclinical studies.
BRCA1, BRCA2 and PARP1, among others, play an important
role in the protection of stalled replication forks, a critical step to
enable replication fork repair after DNA damage [77–79]. In the
absence of the aforementioned proteins, protected forks are ex-
tensively degraded, which leads to cell death. For example,
BRCA2-mutant cells with loss of the MLL3/4 complex protein,
were reported to become PARPi-resistant by fork protection
through reduction of MRE11 recruitment to stalled forks [80].
Yazinski and colleagues further demonstrated that PARP-
inhibitor resistant, BRCA1-deficient cells become dependent on
ATR for survival [81].
Mutations in the DNA-binding domains of PARP1 represent
other likely relevant mechanisms of resistance, although clinical
data are sparse [82]. Similarly, mechanisms that increase
PARylation of PARP1, such as loss of PARG, could lead to
PARPi-resistance by decreasing PARP trapping [83].
Beyond mechanisms rewiring the DNA damage response,
increased expression of ATP-binding cassette transporters, such
as the P-glycoprotein efflux pump have been shown to reduce the
efficacy of PARPi [84].
Closing remarks and future directions
The successful development of PARPi over the last 10 years has
resulted in an effective therapeutic option being available for a
subset of ovarian and breast cancers, with expansion to other
biomarker-driven indications expected in the near future. These
treatments exploit a tumour vulnerability, that in normal condi-
tions makes these tumours more aggressive, and constitutes one
of the prime examples of success in precision medicine to date.
We envision that in the years to come the utility of PARPi will
expand further. First, by better understanding what alterations
beyond BRCA1/2 sensitize different tumour types to PARP inhib-
ition; this will require combining preclinical studies and clinical
trial data. Secondly, by developing more precise assays to stratify
sensitive patients, capturing different predictive biomarkers and,
potentially, combinations of genomic events that when co-
occurring together may be relevant. Facilitating the implementa-
tion of genomics in routine clinical practice will also lead to a
wider population of patients being tested. To accomplish that
aim, we need to provide better resources to physicians to access
these technologies and to support genomic data analyses and
interpretation.
Lastly, rational drug combinations including PARPi may ex-
tend the patient population who may benefit from this drug class
(Figure 3). Combinations with DNA damaging chemotherapy
aim to maximize the effect of DNA damage, but they have been
proved challenging due to overlapping toxicities [85].
Combination with DNA damaging radiation therapy should
nevertheless be explored. Promising preliminary data have been
reported combining PARPi with other targeted agents. This strat-
egy could either aim to create synthetic lethal interactions by tar-
geting several levels of the DNA repair machinery (i.e.
combinations with ATR or HDAC inhibitors) [86, 87], take ad-
vantage of the relation between angiogenesis, hypoxia and DNA
damage [88], or exploit the cross-talk between DDR and hor-
mone receptor-driven pathways, such as ER and AR in breast and
prostate cancer, respectively [89–91].
The advent of immune checkpoint inhibitors has transformed
the management of several tumour types. There is a preclinical
rational suggesting that PARP inhibition may trigger neoantigen
and non-neoantigen-based mechanisms of tumour cell recogni-
tion by the immune system, making PARPi a potential partner
for combination with immune checkpoint inhibitors [92–94]. A
range of clinical trials exploring these combinations are now
underway and may provide evidence of this clinical effect [95].
Optimizing dosage and scheduling of these combinations
requires considering the time necessary for PARP inhibition to
force tumour adaptation.
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